Rifampicin is an essential component of the treatment regimenudfor tuberculosis. Extensive clinical experience has shown that theuddrug is well tolerated, but on rare occasions it can cause life threateningudadverse reactions like acute renal failure and thrombocytopenia. Atudthe Tuberculosis Research Centre, we have treated more than 8000udpatients with pulmonary and extra-pulmonary tuberculosis withudrifampicin-containing regimens over the past 30 years and we areudreporting a case of acute thrombocytopenia probably rifampicinudinduced, in a patient who was retreated for tuberculosis. The physicianudtreating tuberculosis patients must be aware of this rare life threateningudcomplication, which if detected early, is completely reversible.
展开▼
